The role of venlafaxine in the modern treatment of anxiety disorders: a critical update and expert clinical perspectives
Rivista di Psichiatria · 01.07.2026 · 61 (4)
DOI: 10.1708/4747.47641 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Rivista di Psichiatria, erschienen am 01.07.2026. Verfasst von Andrea Fagiolini und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Developmental Medicine, University of Siena, Italy. Hauptthemen laut MEDLINE: Venlafaxine Hydrochloride, Anxiety Disorders, Serotonin and Noradrenaline Reuptake Inhibitors.
Abstract (Originalsprache)
Anxiety disorders are among the leading contributors to global disability and frequently co-occur with major depressive disorder (MDD), chronic pain, and various psychiatric or somatic comorbidities. Effective management of these conditions necessitates a personalized approach informed by current scientific evidence. Extended-release (XR) venlafaxine, a serotonin-noradrenaline reuptake inhibitor, has emerged as a first-line pharmacological option, endorsed by international guidelines for generalized anxiety disorder, panic disorder, and social anxiety disorder. Its dose-dependent dual mechanism, initially serotonergic, progressing to noradrenergic, enables tailored therapeutic strategies aligned with symptom severity. This narrative review, integrating Italian expert consensus and recent literature, highlights the robust efficacy of XR venlafaxine across anxiety disorders, its favorable tolerability profile due to the osmotic pump zero-order release formulation, and its unique capacity to address residual symptoms such as anhedonia and SSRI-induced emotional blunting. Emerging evidence suggests additional roles for venlafaxine in immunomodulation and the promotion of neuroplasticity, which may further enhance its therapeutic benefit. Given the established role of XR venlafaxine as a key therapeutic option in the pharmacological management of anxiety disorders, and acknowledging the impact of CYP2D6 metabolic variability on its efficacy and tolerability, pharmacogenetic testing could be recommended to optimize treatment personalization. It holds particular promise for patients with comorbid or treatment-resistant profiles, offering measurable benefits in quality of life, functional outcomes, and long-term disease management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Molecular and Developmental Medicine, University of Siena, Italy.
- Department of Mental Health and Addiction Services (DSMD), ASST Papa Giovanni XXIII Hospital, Bergamo, Italy - Former President of the Italian Society of Psychiatry, Italy.
- Department of Drug and Health Sciences, University of Catania, Italy - Oasi Research Institute-IRCCS, Unit of Neuropharmacology and Translational Neurosciences, Troina (Enna), Italy.
- Department of Life Science, Health, and Health Professions, Link Campus University, Rome, Italy - Department of Neuroscience, Head-Neck and Chest, Section of Psychiatry, Fondazione Policlinico Universitario Agostino Gem…
- Department of Biomedical and Clinical Sciences, University of Milan, Italy - Department of Mental Health and Addiction Services, ASST Fatebenefratelli-Sacco, Milan, Italy - Department of Psychiatry and Behavioral Scienc…
- Department of Mental Health and Addiction Services, Niguarda Hospital, Milan, Italy.
Zitieren
APA
Fagiolini, A., Bondi, E., Caraci, F., Camardese, G., Dell'Osso, B., Percudani, M., Sani, G., & Fiorillo, A. (2026). The role of venlafaxine in the modern treatment of anxiety disorders: a critical update and expert clinical perspectives. Rivista di Psichiatria, 61(4). https://doi.org/10.1708/4747.47641
Vancouver
Fagiolini A, Bondi E, Caraci F, Camardese G, Dell'Osso B, Percudani M, et al. The role of venlafaxine in the modern treatment of anxiety disorders: a critical update and expert clinical perspectives. Rivista di Psichiatria. 2026;61(4). doi:10.1708/4747.47641
BibTeX
@article{Fagiolini2026,
author = {Fagiolini, Andrea and Bondi, Emi and Caraci, Filippo and Camardese, Giovanni and Dell'Osso, Bernardo and Percudani, Mauro and Sani, Gabriele and Fiorillo, Andrea},
title = {The role of venlafaxine in the modern treatment of anxiety disorders: a critical update and expert clinical perspectives},
journal = {Rivista di Psichiatria},
year = {2026},
volume = {61},
number = {4},
doi = {10.1708/4747.47641}
}
EUVIMED